http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021154122-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_70611ed749d3b0896efb8582a01cb9b0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate | 2021-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc2f1c51f66b1cd70cb2d1739b045c49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a1b81bb79eb5fb16ba7e2c50244ee48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74285b2fed1898f4343eaac067fd433a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7095078f2e066bbb0921495521fbe7a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_420ec02929e32725d2cbe82cdc62b320 |
| publicationDate | 2021-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021154122-A2 |
| titleOfInvention | L-, u-modifications of 5-chloro-n-({(5s)-2-oxo-3-[4-3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide, solvate with dimethyl sulfoxide, methods for producing same, factor xa-inhibiting pharmaceutical compositions based thereon |
| abstract | The invention relates to organic chemistry, and more particularly to novel modifications of the compound 5-chloro-N-({(5S)-2-oxo-3-[4-3-oxo-4-morpholinyl-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide, named L- and U-modifications, a solvate of said compound with dimethyl sulfoxide (DMSO), methods for producing same, as well as pharmaceutical compositions based thereon and the use thereof as a factor Xa inhibitor for treating cardiovascular diseases. The technical result of the invention is that of broadening the range of highly active forms of 5-chloro-N-({(5S)-2-oxo-3-[4-3-oxo-4-morpholinyl-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide and pharmaceutical compositions based thereon which can be used as an Xa factor inhibitor for the treatment and prophylaxis of cardiovascular diseases as a result of the improved solubility of the novel U- and L-modifications and of a solvate thereof with DMSO, as well as that of improving the biological activity of rivaroxaban with respect to factor Xa inhibition while remaining stable for 3 years. |
| priorityDate | 2020-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 74.